Articles related to BRAIN TUMORS

The newly developed Real-CSF test offers a significant leap in diagnosing brain tumors, accurately identifying cancerous lesions in 67% of cases by analyzing cerebrospinal fluid for abnormal genetic material.

The phase 2 trial provides evidence that dabrafenib combined with trametinib could serve as a more effective and safer first-line treatment option for pediatric low-grade gliomas with BRAF V600 mutations. Evaluate the data to consider how this may influence your treatment protocols.

The recent phase 3 trial of vorasidenib in patients with grade 2 IDH-mutant glioma has demonstrated significant improvements in progression-free survival and time to next intervention. Explore the detailed findings to understand how this oral inhibitor could become a vital part of the treatment regimen for this challenging condition.

A recent study on glioma brain tumors reveals the significant role of epigenetic changes in tumor formation. This discovery offers promising avenues for targeted therapies, potentially transforming the approach to treating this devastating disease.

Learn about a ground-breaking strategy for treating uncommon brain tumors like papillary craniopharyngiomas (PCPs), where precision medicine and BRAF/MEK inhibitors marked a major improvement in brain cancer treatment by drastically reducing tumor size.

Amar Gajjar, MD, who serves as the co-chair of the oncology department and chair of the pediatric medicine department at St. Jude Children’s Research Hospital in Memphis, Tennessee, answers questions from our friends at Cancer Therapy Advisor. Proton therapy, conventional chemotherapy, targeted therapies, and observed glioma progression are all topics covered by Dr. Gajjar when talking about treatment options for pediatric low-grade gliomas (pLGG) that have relapsed or progressed.